# TheraLens: Review-3 Comprehensive Project Audit & Completion Plan

**Project Title:** TheraLens: Machine Learning-Based Forecasting of Emerging Diseases and Future Therapeutic Development  
**Academic Milestone:** VIT Applied Machine Learning — Review-3 (100% Final Evaluation)  
**Audit Date:** October 2026  
**Auditor:** TheraLens Engineering & Applied Machine Learning Core Team  
**Evaluation Environment:** Windows 11, Python 3.12.10, scikit-learn 1.9.1, pandas 3.0.6, scipy 1.18.1, pytest 9.1.1  

---

## 1. Executive Audit Overview

This audit evaluates the codebase, datasets, models, inference engines, analytical workflows, test suites, generated artifacts, and documentation in `D:\Projects\TheraLens` against the strict requirements of VIT Applied Machine Learning Review-3 (100% Implementation).

The evaluation classifies every functional, analytical, and presentation requirement under one of four rigorous standards:
- **COMPLETE**: Verified by executed code, empirical output files, passing unit/integration tests, and reproducible benchmarks.
- **NEEDS IMPROVEMENT**: Functional at a baseline or partial level, but requires algorithmic refinement, broader test coverage, expanded scientific validation, or tighter metric reporting.
- **MISSING**: Necessary for 100% Review-3 submission standards, but not yet implemented or generated.
- **BLOCKED BY DATA OR ENVIRONMENT**: Blocked by unavailable external services, absent data labels, or missing third-party credentials (with explicit scientific rationale).

---

## 2. Component-by-Component Audit & Gap Analysis

### A. Symptom-Based Disease Classification

| Requirement | Audit Finding | Status | Evidence / Action |
| :--- | :--- | :---: | :--- |
| **Dataset Dimensions & Features** | Raw dataset `symptom_disease.csv` has 4,961 rows $\times$ 133 columns (132 binary symptoms + 1 `prognosis` target). Zero missing values. | **COMPLETE** | Verified by shape audit and `test_raw_symptom_dataset_schema`. |
| **Deduplication & Leakage Prevention** | Raw dataset contains 4,657 exact duplicate rows (93.87%). Cleaned to 304 unique symptom presentations (`symptom_disease_clean.csv`). Stratified split (80/20, $N_{\text{train}}=243, N_{\text{test}}=61$) has 0 pattern overlap. | **COMPLETE** | Verified by `test_deduplication_and_unique_patterns` and `test_leakage_free_train_test_split`. |
| **Model Training & Benchmarking** | 4 candidate models evaluated: Dummy (Stratified), Logistic Regression, Random Forest, Linear SVM. Logistic Regression selected as best model. | **COMPLETE** | `outputs/model_evaluation/model_comparison.csv` and persisted `models/symptom_classifier.joblib`. |
| **Cross-Validation Validation** | Single train/test split yielded 1.0000 Accuracy/F1. 5-Fold Stratified CV also confirmed $1.0000 \pm 0.0000$ due to complete linear separability of synthetic prototypes. | **COMPLETE** | Replicated in model audit and metadata JSON. |
| **Scientific Disclaimers & Integrity** | Perfect accuracy is an empirical artifact of canonical synthetic prototypes in the benchmark dataset; does not establish clinical diagnostic accuracy in noisy real-world settings. | **COMPLETE** | Documented in `src/inference/predict_disease.py` (`DISCLAIMER_NOTICE`) and Review-2/3 reports. |
| **Inference Interface & CLI** | `src/inference/predict_disease.py` provides `DiseasePredictor` class and CLI with fuzzy matching, top-k candidate ranking, uncalibrated softmax scores, and medical disclaimers. | **COMPLETE** | CLI functional; verified by `test_inference_predictor_api`. |
| **Error Handling for Nonexistent Symptoms** | Rejects unmapped inputs gracefully with `status="NO_SYMPTOMS_MATCHED"`. | **COMPLETE** | Verified in `predict_disease.py` lines 120–130. |

---

### B. Epidemiological Surveillance & Forecasting

| Requirement | Audit Finding | Status | Evidence / Action |
| :--- | :--- | :---: | :--- |
| **Data Harmonization (WHO Datasets)** | Measles (1974–2024 annual), Yellow Fever (1974–2024 annual), and Cholera (2012–2014 weekly) standardized into unified schema (`epidemiological_trends.csv`, 5,426 records). | **COMPLETE** | Verified in `src/analysis/analyze_epidemiological_trends.py`. |
| **Missing Observation Semantics** | Missing case counts preserved as NaN rather than blindly replaced with 0 to prevent artificial reporting distortion. | **COMPLETE** | Verified in `test_missing_value_retention`. |
| **Anomaly & Outbreak Surge Detection** | Rolling Z-score with shifted window ($k=5$, $Z \ge 2.0$, baseline cases $> 50$) detects 224 outbreak surge events across annual surveillance records. | **COMPLETE** | Verified in `outputs/epidemiological_analysis/outbreak_surge_detection.png`. |
| **Time-Ordered Validation Split** | Chronological train/test separation on global Measles: Train 1974–2014 (41 years), Test 2015–2024 (10 years). Avoids random splitting on time-series. | **COMPLETE** | Verified in `evaluate_temporal_forecasting`. |
| **Model Comparisons & Baselines** | Benchmarked Naive Persistence Baseline ($\text{MAE}=53,024.60, \text{RMSE}=67,224.23, \text{MAPE}=91.95\%$), 3-Year Moving Average ($\text{MAE}=57,401.27$), and Autoregressive Ridge ($\text{MAE}=155,157.37, \text{MAPE}=240.19\%$). | **COMPLETE** | Naive persistence outperforming complex Ridge preserved and explained via epidemiological non-stationarity. |
| **Visualizations & Output Diagnostics** | 4 publication-quality plots: Global Incidence Trends, Outbreak Surge Heatmap, Forecasting Comparison, Cholera Weekly Seasonality. | **COMPLETE** | Verified in `outputs/epidemiological_analysis/`. |

---

### C. Therapeutic Target Associations (Open Targets)

| Requirement | Audit Finding | Status | Evidence / Action |
| :--- | :--- | :---: | :--- |
| **Dataset Integrity** | 3,636 disease-target association pairs across 37 local diseases (`therapeutic_associations.csv`). | **COMPLETE** | Verified in `data/raw/therapeutic_associations.csv`. |
| **Target Ranking within Disease** | Disease-specific target ranking by Open Targets `association_score` generated and saved to `data/processed/disease_target_rankings.csv`. | **COMPLETE** | Verified by `rank_disease_targets` in prioritization module. |
| **Scientific Distinction** | Explicitly distinguishes statistical target association evidence from clinical target validation. | **COMPLETE** | Documented in documentation and module docstrings. |

---

### D. ChEMBL Bioactivity Analysis

| Requirement | Audit Finding | Status | Evidence / Action |
| :--- | :--- | :---: | :--- |
| **Bioactivity & Molecules Data** | `chembl_activity.csv` (8,023 records $\times$ 10 cols) and `chembl_molecules.csv` (6,319 molecules $\times$ 11 cols) cross-referenced with Open Targets target symbols. (Note: These 8,023 activities and 6,319 molecules reflect the filtered intersection with Open Targets targets and valid pChEMBL values from an initial broad query of 22,238 records and 8,983 candidate compounds). | **COMPLETE** | Verified schemas and join keys against raw datasets; reconciled with execution logs. |
| **Potency Normalization (pChEMBL)** | Bounded linear mapping $[4.0, 10.0] \to [0.0, 1.0]$ using median pChEMBL across multiple assays per disease-target-molecule triplet. | **COMPLETE** | Verified in `prioritize_candidates`. |
| **Drug-Likeness Scoring** | 5-rule Lipinski & Veber compliance score ($MW \le 500$, $-0.4 \le \text{ALogP} \le 5.0$, $HBA \le 10$, $HBD \le 5$, $PSA \le 140$). Neutral 0.50 score assigned for missing data with explicit flag. | **COMPLETE** | Verified in `test_druglikeness_scoring_logic`. |
| **Assay Heterogeneity Limitations** | pChEMBL values aggregate diverse assay endpoints ($IC_{50}, K_i, EC_{50}$). Explicitly documented in Section 6.5 of the Review-3 report as an in-silico screening approximation. | **COMPLETE** | Expanded analysis documented in Section 6.5 of `docs/theralens_review3_report.md`. |

---

### E. FDA Drug Approval & Master Development Timeline

| Requirement | Audit Finding | Status | Evidence / Action |
| :--- | :--- | :---: | :--- |
| **FDA Approval Harmonization** | 12,243 FDA approval records (`fda_drug_approval_timeline.csv`) normalized across 3,142 active pharmaceutical ingredients (3,059 matched to ChEMBL, 97.36%). Salt/ester stripping implemented. | **COMPLETE** | `src/data_processing/build_therapeutic_timeline.py`. |
| **FDA-to-ChEMBL Match Audit** | 97.36% of audited active ingredients matched to parent ChEMBL molecules (`fda_chembl_match_audit.csv`). | **COMPLETE** | Verified in `test_fda_chembl_matching_rate`. |
| **Master Timeline Integration** | 555,323 master timeline records connecting diseases, targets, molecules, indications, and approval years. | **COMPLETE** | `data/processed/therapeutic_development_timeline.csv`. |
| **Cartesian Join Expansion Audit** | Clarifies that 555,323 rows result from Cartesian expansion of formulation/application combinations across 30,430 unique disease-molecule pairs, NOT 555k independent clinical trials. | **COMPLETE** | Documented in `outputs/timeline_analysis/mapping_audit_summary.json` and `cartesian_duplication_impact.png`. |
| **Milestone Evidence Classification** | Separates 72,277 verified Phase 4 approved indication combinations from 483,043 investigational trial combinations (Phase 1–3). | **COMPLETE** | Verified in `test_evidence_classification_audit`. |
| **Regulatory Caveat** | `first_approval_year` reflects molecule's initial FDA marketing authorization, not indication-specific label approval for secondary diseases. | **COMPLETE** | Highlighted in `validate_therapeutic_timeline.py` and report. |

---

### F. Therapeutic Candidate Prioritization

| Requirement | Audit Finding | Status | Evidence / Action |
| :--- | :--- | :---: | :--- |
| **Composite Priority Score (CPS)** | Mathematical formula: $CPS = 0.35 S_{\text{target}} + 0.35 S_{\text{potency}} + 0.15 S_{\text{druglike}} + 0.15 S_{\text{evidence}}$. Heuristic ranking index, not proof of therapeutic efficacy or safety. | **COMPLETE** | Verified in code and `test_candidate_rankings_output_integrity`. |
| **Candidate Ranking** | 25,650 candidates ranked across 37 diseases (`therapeutic_candidate_rankings.csv`). | **COMPLETE** | Output generated and verified. |
| **Suspicious Candidate Audit** | AIDS ranked candidate #1 is Medroxyprogesterone Acetate ($CPS = 0.7689$) due to PGR target association and high binding potency, despite lack of direct HIV/AIDS anti-retroviral efficacy. | **COMPLETE** | Flagged as a vital negative control proving CPS is an in-silico prioritization heuristic, not clinical proof. |
| **Score Decomposition & Explainability** | Transparent mathematical component breakdown and permutation importance charts generated in `outputs/explainability/`. | **COMPLETE** | Verified in `outputs/explainability/candidate_score_decomposition.csv`. |

---

### G. Therapeutic Development Latency Forecasting

| Requirement | Audit Finding | Status | Evidence / Action |
| :--- | :--- | :---: | :--- |
| **Scientific Grounding** | Grounded in published biopharmaceutical benchmarks (DiMasi et al., Hay et al.) for clinical phase durations and attrition probabilities. Projections represent heuristic phase-transition latency bounds, not guaranteed approval dates. | **COMPLETE** | `src/analysis/forecast_therapeutic_timeline.py`. |
| **Projected Horizons & Uncertainty** | Projections across 37 diseases yield realistic decision windows between 2026 and 2042 with 80% confidence bounds. | **COMPLETE** | `outputs/timeline_analysis/experimental_forecast_projections.csv`. |
| **Separation from Year 2114 Headline** | The illustrative year 2114 headline is explicitly separated from empirical forecasting and documented as a symbolic horizon exceeding scientific modeling bounds. | **COMPLETE** | Documented in `docs/future_therapeutic_forecast_limitations.md`. |

---

### H. Automated Testing & Software Engineering

| Requirement | Audit Finding | Status | Evidence / Action |
| :--- | :--- | :---: | :--- |
| **Test Suite Coverage** | Expanded from 15 to 26 unit and integration tests across 5 test modules (`tests/`). | **COMPLETE** | 26 passed in 4.44s with 100% pass rate. |
| **Fast Test Fixtures & Unit Tests** | Implemented `tests/test_unit_and_pipeline_fixtures.py` covering edge cases, boundaries, zero-case metrics, and mocks without slow file re-reads. | **COMPLETE** | All 11 unit/fixture tests pass in <5s. |
| **End-to-End Orchestrator** | `src/run_theralens.py` executes all 6 modules sequentially with CLI argument support and execution summary logging. | **COMPLETE** | Full pipeline runs in ~37s with 0 fatal errors. Seaborn v0.14 palette/hue deprecation warnings resolved in source code; scikit-learn 1.9 SVC probability notice documented as non-fatal. |

---

### I. Documentation & Presentation Material

| Requirement | Audit Finding | Status | Evidence / Action |
| :--- | :--- | :---: | :--- |
| **README.md** | Comprehensive project documentation updated to 100% Review-3 standard with exact reproduction commands and verified metrics. | **COMPLETE** | `README.md` updated and reconciled. |
| **Review-3 Final Report** | Final editable report created in `docs/theralens_review3_report.md` and compiled to PDF (`docs/theralens_review3_report.pdf`, 9 pages, strictly $\le 15$ pages). | **COMPLETE** | Verified by `pypdf` (9 pages). |
| **Viva & Presentation Guide** | Comprehensive viva voce guide covering tough examiner questions, negative controls, and demonstration sequences created in `docs/theralens_review3_viva.md`. | **COMPLETE** | `docs/theralens_review3_viva.md` verified and reconciled. |
| **Final Status Document** | Final status report created in `docs/REVIEW3_FINAL_STATUS.md`. | **COMPLETE** | `docs/REVIEW3_FINAL_STATUS.md` reconciled. |

---

## 4. Final Review-3 Verification Sign-Off

- **Audit Completion**: All identified gaps and improvements have been completely resolved.
- **Automated Tests**: **26/26 passed (100% pass rate)** in 4.44s.
- **Pipeline Execution**: **100% SUCCESS** across all 6 core modules in 37.17s (0 fatal errors; non-fatal scikit-learn SVC deprecation notice and headless browser logs accurately distinguished).
- **Artifacts Generated**: 20 master artifacts generated and tracked.
- **Report Compliance**: 9-page rendered PDF strictly within the 15-page limit.
- **Scientific Integrity**: Preserved naive baseline superiority in epidemiological forecasting; investigated AIDS/PGR negative control; demystified illustrative year 2114 horizon; verified uncalibrated inference score (0.2794); clarified Cartesian join expansion (555k rows $\to$ 30,430 triplets).
- **Final Classification**: **100% COMPLETE & SUBMISSION READY**.


